You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)建議人民幣股份發行並在科創板上市
格隆匯 02-03 17:04

格隆匯 2 月 3日丨中國生物製藥(01177.HK)發佈公吿,2021年2月3日,董事會已批准可能進行人民幣股份發行並在上交所科創板上市的初步建議。建議境內發行須取決並受限於市況、股東於公司股東大會上批准以及必要的監管批准。

建議境內發行項下將予發行的人民幣股份不得超過緊接該發行前香港股份總數及建議境內發行項下擬發行的人民幣股份數目之和的10%。在符合中國適用法律及法規的情況下,就不超過該初始發行的人民幣股份數目15%的超額配售權可被授出。人民幣股份將全為新發行股份,並不涉及現有股份的轉換。扣除發行費用後,建議境內發行的募集資金初步計劃用於發展公司的主營業務、業內併購及整合,以及一般營運資金。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account